Premium
Methylphenidate in mildly depressed outpatients
Author(s) -
Rickels Karl,
Gingrich Russell L.,
Mclaughlin F. W.,
Morris Richard J.,
Sablosky Lester,
Silverman Howard,
Wentz Henry S.
Publication year - 1972
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1972134595
Subject(s) - methylphenidate , placebo , apathy , volunteer , concomitant , medicine , anesthesia , placebo group , psychiatry , attention deficit hyperactivity disorder , alternative medicine , disease , agronomy , biology , pathology
A double‐blind placebo‐controlled trial of methylphenidate (30 mg. per day) was conducted with 101 general practice and symptomatic volunteer patients diagnosed as mildly to moderately depressed with concomitant fatigue or apathy. Patient but not physician measures demonstrated significantly more improvement with methylphenidate than with placebo. More than 50 per cent of the patients reported side effects, somewhat unexpectedly. Patients on placebo reported side effects as frequently as did those on methylphenidate.